Stay updated with breaking news from Curis Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
JATT Acquisition (NYSE:JATT – Get Free Report) and Curis (NASDAQ:CRIS – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings. Institutional & Insider Ownership 48.0% of JATT Acquisition […]
JATT Acquisition (NYSE:JATT – Get Free Report) and Curis (NASDAQ:CRIS – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings. Valuation & Earnings This table compares JATT Acquisition […]
Scinai Immunotherapeutics (NASDAQ:SCNI – Get Free Report) and Curis (NASDAQ:CRIS – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends. Analyst Ratings This is a summary of current […]
Scinai Immunotherapeutics (NASDAQ:SCNI – Get Free Report) and Curis (NASDAQ:CRIS – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings and dividends. Profitability This table compares Scinai Immunotherapeutics and Curis’ […]
HC Wainwright reaffirmed their buy rating on shares of Curis (NASDAQ:CRIS – Free Report) in a research report report published on Wednesday morning, Benzinga reports. They currently have a $26.00 price target on the biotechnology company’s stock. Separately, Cantor Fitzgerald restated an overweight rating on shares of Curis in a report on Wednesday. Get Our […]